methylmalonic acid has been researched along with Parkinson Disease in 7 studies
Methylmalonic Acid: A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. Abnormalities in methylmalonic acid metabolism lead to methylmalonic aciduria. This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl CoA.
methylmalonic acid : A dicarboxylic acid that is malonic acid in which one of the methylene hydrogens is substituted by a methyl group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The urine levels of MMA and serum levels of Hcy as well as folic acid and vitamin B(12) were measured in patients suffering from the distinct neurodegenerative diseases progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), and compared to age- and gender-matched control subjects." | 7.76 | Elevated levels of methylmalonate and homocysteine in Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. ( Bötzel, K; Giese, A; Levin, J; Lorenzl, S; Vogeser, M, 2010) |
| "Methylmalonic aciduria (MMA-uria) is seen in several inborn errors of metabolism (IEM) affecting intracellular cobalamin pathways." | 3.91 | ( Andréasson, M; Svenningsson, P; von Döbeln, U; Wedell, A; Zetterström, RH, 2019) |
| "The urine levels of MMA and serum levels of Hcy as well as folic acid and vitamin B(12) were measured in patients suffering from the distinct neurodegenerative diseases progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), and compared to age- and gender-matched control subjects." | 3.76 | Elevated levels of methylmalonate and homocysteine in Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. ( Bötzel, K; Giese, A; Levin, J; Lorenzl, S; Vogeser, M, 2010) |
| "The severity of neuropathic pain was evaluated using total neuropathy scale, revised (TNSr), and Korean Neuropathic Pain Questionnaire (KNPQ)." | 1.46 | Serum methylmalonic acid correlates with neuropathic pain in idiopathic Parkinson's disease. ( Kang, K; Ko, PW; Lee, HW; Park, D; Park, JS, 2017) |
| " Cumulative lifetime L-dopa dosage and fasting MMA levels were associated with PN severity." | 1.35 | Neuropathy as a potential complication of levodopa use in Parkinson's disease. ( Brown, MS; Furtado, S; Suchowersky, O; Toth, C; Zochodne, D, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Paul, DA | 1 |
| Qureshi, ARM | 1 |
| Rana, AQ | 1 |
| Park, JS | 1 |
| Park, D | 1 |
| Ko, PW | 1 |
| Kang, K | 1 |
| Lee, HW | 1 |
| Andréasson, M | 1 |
| Zetterström, RH | 1 |
| von Döbeln, U | 1 |
| Wedell, A | 1 |
| Svenningsson, P | 1 |
| Yap, AC | 1 |
| Mahamad, UA | 1 |
| Lim, SY | 1 |
| Kim, HJ | 1 |
| Choo, YM | 1 |
| Toth, C | 2 |
| Brown, MS | 1 |
| Furtado, S | 1 |
| Suchowersky, O | 2 |
| Zochodne, D | 1 |
| Breithaupt, K | 1 |
| Ge, S | 1 |
| Duan, Y | 1 |
| Terris, JM | 1 |
| Thiessen, A | 1 |
| Wiebe, S | 1 |
| Zochodne, DW | 1 |
| Levin, J | 1 |
| Bötzel, K | 1 |
| Giese, A | 1 |
| Vogeser, M | 1 |
| Lorenzl, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Daily Anti-inflammatory Supplementation on Foundation Pain Index Scores in Chronic Opiate Patients[NCT05896878] | 20 participants (Anticipated) | Interventional | 2023-07-10 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for methylmalonic acid and Parkinson Disease
| Article | Year |
|---|---|
Peripheral neuropathy in Parkinson's disease.
Topics: Humans; Levodopa; Methylmalonic Acid; Parkinson Disease; Peripheral Nervous System Diseases; Vitamin | 2020 |
6 other studies available for methylmalonic acid and Parkinson Disease
| Article | Year |
|---|---|
Serum methylmalonic acid correlates with neuropathic pain in idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Cross-Sectional Studies; Female; Homocysteine; Humans; Levod | 2017 |
Topics: Aged; Dementia; Humans; Male; Metabolism, Inborn Errors; Methylmalonic Acid; Mutation; Parkinson Dis | 2019 |
A coumarin-based fluorescent probe as a central nervous system disease biomarker.
Topics: Biomarkers; Biosensing Techniques; Coumarins; Fluorescent Dyes; Homocysteine; Humans; Methylmalonic | 2014 |
Neuropathy as a potential complication of levodopa use in Parkinson's disease.
Topics: Analysis of Variance; Antiparkinson Agents; Female; Homocysteine; Humans; Levodopa; Male; Methylmalo | 2008 |
Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Databases, Factual; Fasting; Female; Humans; Levodopa; M | 2010 |
Elevated levels of methylmalonate and homocysteine in Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis.
Topics: Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Case-Control Studies; Female; Folic Acid; Ho | 2010 |